trial

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCTId NCT01469039
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 623 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2014-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
623 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-12
Primary completion
2014-01
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ALKS 9072

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

84 total
Little Rock, United StatesLittle Rock, United StatesSpringdale, United StatesCerritos, United StatesGarden Grove, United StatesLa Habra, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesWashington D.C., United StatesFort Lauderdale, United States

Linked catalysts

1
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripipra — primary completion2014-01

Facts & assertions

4 sourced
Enrollment
623
Phase
PHASE3
Primary Completion Date
2014-01
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 9072
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person